Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Prostatic Neoplasms 85Lung Neoplasms 63Carcinoma, Non-Small-Cell Lung 50Neoplasm Metastasis 48Breast Neoplasms 48Glioma 41Glioblastoma 38Pancreatic Neoplasms 35Multiple Myeloma 35Brain Neoplasms 34Carcinoma, Renal Cell 32Lymphoma, Large B-Cell, Diffuse 29Melanoma 28Urinary Bladder Neoplasms 27Colorectal Neoplasms 27Squamous Cell Carcinoma of Head and Neck 25Ovarian Neoplasms 24Triple Negative Breast Neoplasms 21Oropharyngeal Neoplasms 21Carcinoma, Hepatocellular 21Lymphoma 20Mouth Neoplasms 18Lymphoma, Follicular 18Sarcoma 17Fallopian Tube Neoplasms 16Carcinoma 16Laryngeal Neoplasms 15Carcinoma, Transitional Cell 15Astrocytoma 15Lymphoma, Mantle-Cell 14

Interventions

Cyclophosphamide 11Dexamethasone 10Cytarabine 10Vincristine 8Methotrexate 7merphos 5Mercaptopurine 5Doxorubicin 5venetoclax 4pegaspargase 4dexamethasone acetate 4dexamethasone 21-phosphate 4blinatumomab 4azathiopurine 4auricularum 4Specimen Handling 4Prednisone 4Leucovorin 4Inotuzumab Ozogamicin 4Calcium Dobesilate 4prednylidene 3deltacortene 3Thioguanine 3N,N-dicyclohexyl-isoborneol-10-sulfonamide 3Methylprednisolone 3Asparaginase 3calaspargase pegol 2asparaginase erwinia chrysanthemi recombinant 2Spinal Puncture 2Rituximab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma × Magnetic Resonance Spectroscopy × 1 year × Clear all
NCT03504644 2026-05-29

Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia

Eastern Cooperative Oncology Group

Phase 1/2 Active not recruiting
40 enrolled 18 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03959085 2026-05-05

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Children's Oncology Group

Phase 3 Recruiting
5,951 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Biphenotypic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡